Medeiros JFP, de Oliveira Borges MV, Soares AA, et al
The Difference Between OFF and Parkinsons Dyskinesia
Click the link below to learn more about our Performance Recovery bag
Data from January 2021 through May 2023 Source: IQVIA LAAD pharmacy and medical claims
Multiple cardiovascular outcome trials (ELIXAlixisenatide, LEADERliraglutide, SUSTAIN-6semaglutide, EXSCELexenatide, Harmony Outcomesalbiglutide, REWINDdulaglutide, and PIONEER-6oral semaglutide) have reported, to a greater or lesser extent, improvements in cardiovascular outcomes, with a systematic review and meta-analysis of these trials involving a combined total of 56,004 participants showing that these drugs as a class reduced major adverse cardiovascular events by 12%, death from cardiovascular causes by 12%, fatal or nonfatal stroke by 16%, and fatal or nonfatal myocardial infarction by 9%